Four Simple Blood Values May Unmask IVIG Failure in Kawasaki Disease

Key Takeaway: A composite blood marker, the HALP score, calculated from hemoglobin, albumin, lymphocyte count, and platelet count, can predict which children with Kawasaki disease will be resistant to standard intravenous immunoglobulin (IVIG) therapy. Early identification of these children may allow physicians to escalate treatment before irreversible heart damage occurs.

Racing the Clock for a Child’s Heart

Imagine a five-year-old with a persistent fever, bloodshot eyes, a strawberry-red tongue, and peeling fingertips. The pediatrician suspects Kawasaki disease, an inflammatory condition that attacks blood vessels throughout the body and, if inadequately treated, can lead to coronary artery aneurysms that haunt a child for life. Standard therapy—a high-dose immunoglobulin infusion—succeeds in about nine out of ten cases. But for the child in that tenth chair, the stakes are immense. Until now, predicting who will fail first-line treatment has been an imprecise endeavor. A new study reveals that a simple, low-cost blood score could dramatically change that equation.

Kawasaki Disease: A Primary Threat to Childhood Heart Health

First described in 1967 by Japanese pediatrician Tomisaku Kawasaki, Kawasaki disease is an acute vasculitis—an inflammatory assault on medium-sized arteries—that predominantly targets children under five years of age^[2]. In developed nations, it has surpassed rheumatic fever as the most common cause of acquired heart disease in children^[3]. The coronary arteries are the disease’s favored target. If not treated in time, approximately 25% of affected children develop coronary artery abnormalities, including aneurysms that can lead to heart attacks, clot formation, or sudden death years later^[4]. The introduction of high-dose IVIG therapy in the 1980s was transformative, reducing the rate of coronary complications to below 5%^[5]. However, a stubborn minority of patients—typically 10% to 20%—remain febrile after IVIG and face a significantly higher risk of coronary damage^[6]. Identifying these children before treatment begins, rather than waiting 36 hours to see if the fever breaks, is one of the most pressing challenges in pediatric cardiology.

What the Researchers Did

A group of researchers analyzed data from 598 children diagnosed with Kawasaki disease. Of these children, 58—or 9.7% of the cohort—were found to be resistant to standard IVIG therapy. For each child, the investigators calculated a composite marker called the HALP score. This score combines four routine laboratory values: hemoglobin, albumin, lymphocyte count, and platelet count. All four are obtained from tests nearly every hospital performs on admission—a standard complete blood count and a basic metabolic panel. No exotic assays, no expensive genomic tests, and no waiting days for results.

The team then compared the HALP score’s ability to predict IVIG resistance against other well-known inflammatory ratios, such as the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR). Predictive accuracy was measured using the area under the receiver operating characteristic curve (AUC), a statistical measure where 1.0 indicates perfect prediction and 0.5 is no better than a coin toss.

The Findings

A low HALP score emerged as an independent risk factor for IVIG resistance. Its overall predictive accuracy was impressive: with an AUC of 0.854, it significantly outperformed both the NLR (AUC = 0.751) and the PLR (AUC = 0.793)^[1]. Perhaps the most striking results were found in patients at the extremes of age. In infants six months or younger, the HALP score achieved an AUC of 0.934. In children 48 months and older, it reached 0.947—figures that approach the kind of accuracy clinicians dream of in diagnostic medicine.

Why the HALP Score Works: The Biology Behind the Numbers

Each component of the HALP score reflects a different facet of the inflammatory storm that defines Kawasaki disease. Hemoglobin often drops during severe systemic inflammation because pro-inflammatory cytokines suppress red blood cell production in the bone marrow and shorten red cell lifespan—a phenomenon known as anemia of inflammation^[7]. Albumin, the most abundant protein in blood plasma, falls as capillary leak syndrome allows it to seep into tissues and as the liver shifts its synthetic machinery toward acute-phase reactants like C-reactive protein^[8]. Lymphocyte counts plummet as activated T cells migrate out of the bloodstream and into inflamed vessel walls, and as cytokine-induced apoptosis reduces their numbers. While platelet counts are often high in the subacute phase of Kawasaki disease, they can be paradoxically consumed early in severe cases through microthrombus formation on damaged coronary endothelium.

A low HALP score is therefore not just a number; it is a biochemical portrait of a child whose inflammatory response has overwhelmed the body’s compensatory reserves. It captures the depth and breadth of the vascular injury in a way that single markers cannot.

What This Means for Families and Clinicians

For parents navigating the terrifying hours after a Kawasaki disease diagnosis, this research offers a tangible reason for hope. Instead of a “wait-and-see” approach—administering IVIG and hoping the fever breaks—clinicians armed with the HALP score can perform risk stratification at the bedside, at the moment of admission, using blood tests that are already being drawn. Children flagged as high-risk may be candidates for intensified initial therapies, such as adjunctive corticosteroids or infliximab, which are promising strategies in IVIG-resistant populations^[9]. The goal is clear: intervene earlier, more aggressively, and preserve the coronary arteries.

The score’s exceptional performance in infants younger than six months is particularly valuable. These youngest patients often present atypically—without the classic picture of rash, conjunctivitis, and swollen lymph nodes—delaying diagnosis and making treatment resistance more dangerous. A reliable, objective predictor in this age group illuminates a true clinical blind spot.

The global incidence of Kawasaki disease has been rising, primarily in East Asia, and children with coronary aneurysms require lifelong follow-up. Ongoing studies are refining diagnostic tools, risk scores, and advanced treatments. Research is also exploring potential links between its rising incidence and inflammatory syndromes associated with COVID-19^[10].

Key Limitations

A single study, no matter how compelling, does not rewrite clinical guidelines. This was a retrospective analysis, where researchers looked back at existing records rather than testing the score prospectively in real time. While the 9.7% resistance rate is consistent with published literature, it reflects the patient population of a single institution, and the HALP score’s cutoff values will need to be validated in different ethnic and geographic cohorts. The incidence and severity of Kawasaki disease vary significantly by race and geography, with the highest rates observed in East Asian populations. Whether the score performs equally well in North American or European children requires confirmation. Prospective, multicenter studies are a mandatory next step before the HALP score can be formally incorporated into treatment algorithms.

Still, the elegance of this approach—turning four lab values that every emergency department already collects into a predictive tool of this caliber—represents the kind of creative, patient-centered innovation that pediatric medicine needs. Sometimes the most powerful diagnostic breakthroughs don’t come from new technologies. They come from looking at old data with new eyes.

Scientific Sources

1. Li K, et al. Predictive value of the hemoglobin-albumin-lymphocyte-platelet score for intravenous immunoglobulin resistance in children with Kawasaki disease. Italian journal of pediatrics. 2026;52(1). PubMed: https://pubmed.ncbi.nlm.nih.gov/42286758/
2. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 1967;16(3):178-222.
3. McCrindle BW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017; 25;135(17):e927-e999.
4. Kato H, et al. Long-term consequences of Kawasaki disease: a 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94(6):1379-1385.
5. Newburger JW, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324(23):1633-1639.
6. Burns JC, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J. 1998;17(12):1144-1148.
7. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-1023.
8. Nicholson JP, et al. The role of albumin in critical illness. Br J Anaesth. 2000;85(4):599-610.
9. Tremoulet AH, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9930):1731-1738.
10. Kuo, H. Diagnosis, Progress, and Treatment Update of Kawasaki Disease. International Journal of Molecular Sciences, Int J Mol Sci; 2023: 11;24(18):13948.